Anticataract activity of Kohl-Chikni Dawa--a compound ophthalmic formulation of Unani medicine in alloxan-diabetic rats.
Kohl-Chikni Dawa (KCD), a compound ophthalmic formulation of Unani medicine was studied for anticataract activity in alloxan-diabetic rats. When one drop of 3% KCD solution was applied (once and twice daily) in both eyes for 90 days in alloxan-diabetic rats, a significant reduction of lens opacification was noticed. On the other hand, local application of 3% KCD solution (once and twice daily) did not reduce the blood sugar concentration in normal and alloxan-diabetic rats. Blood sugar in all the rats was estimated by glucometer and the morphological changes of the lenses were examined by slit-lamp biomicroscope before and after therapy at various time intervals for 90 days. These results suggest that the local application of 3% KCD solution possesses anticataract effect in alloxan-induced hyperglycaemic rats.